RASolute 302 Subgroup Insights for Daraxonrasib in Pancreatic Cancer

Additional analyses from the RASolute 302 trial offer further insight into daraxonrasib, a pan-RAS inhibitor, compared with chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma. The discussion focuses on outcomes by RAS mutational status, with particular attention to the small group of patients with RAS wild-type disease. The panel explains how disagreement between investigator assessment and blinded independent central review affected progression-free survival results in that subgroup. They explain why overall survival, which still favored daraxonrasib, carries more weight. They describe the data as reinforcing daraxonrasib as a standard of care in refractory metastatic disease. They also look ahead to real-world evidence following approval and to ongoing studies in earlier lines, in perioperative settings and in combination with allele-specific KRAS inhibitors. A patient example shows a rapid drop in tumor markers and relief of pain. The conversation closes with practical advice on counseling patients about skin toxicity, including preventive steroid creams, sunscreen and involving family members to support adherence.